We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Get Up to $500 of Free Promega Reagents with our Back to the Bench Program. Register Now ›

PD-1+TIGIT Combination Bioassay

Measure potency and stability of biologics designed to block immune checkpoint signals

  • Prequalified according to ICH guidelines
  • 96- and 384-well plate formats
  • No primary cell culture required

Choose an option

Catalog number selected: J2211

$ 1,430.00
Your price:
Add to Cart
This product is discontinued
PD-1+TIGIT Combination Bioassay
1 each
$ 1,430.00
Your price: Log in
Change Configuration
32454752-overview

Measure the ability of biologics to block immune checkpoint signals

PD-1 and TIGIT are both immune inhibitory receptors that are expressed on T cells. Engagement of PD-1 by PD-L1 on an adjacent cell inhibits TCR signaling and TCR-mediated proliferation, transcriptional activation and cytokine production. The ligand for TIGIT is CD155. TIGIT negatively regulates NK cell killing and T cell activation by competing with CD226 for binding to CD155 and by directly interfering with CD226 homodimerization.

Preclinical cancer studies suggest that targeted therapies that simultaneously block PD-1 and TIGIT are superior to those that block either pathway alone. The PD-1+TIGIT Combination Bioassay reflects the mechanism of action (MOA) of biologics designed to block the PD-1/PD-L1 and TIGIT/CD155 interactions. 

32454752-assaycomponents-background

Assay Components

The assay consists of two genetically engineered cell lines:

PD-1+TIGIT Effector Cells: Jurkat T cells engineered to express human PD-1 and human TIGIT with a luciferase reporter driven by a native promoter that can respond to both TCR activation and CD226 co-stimulation

PD-L1+CD155 aAPC/CHO-K1 Cells: CHO-K1 cells engineered to express human PD-L1 and human CD155 with an engineered cell-surface protein designed to activate the TCR complex in an antigen-independent manner

When the two cell types are co-cultured,PD-1 binds to PD-L1 and inhibits TCR-induced activation and promoter-mediated luminescence. Addition of an anti-PD-1 Ab or an anti-TIGIT Ab blocks the interaction of PD-1 with PD-L1 or TIGIT with CD155, respectively, and results in a modest enhancement in promoter-mediated luminescence. Addition of antibodies that block both PD-1/PD-L1 and TIGIT/CD155 will result in much higher promoter-mediated luminescence due to synergy between these pathways.

The Workflow

Traditional Method

Standard bioassay workflow with cultured cells

'Cells as reagents' Method

Improved bioassay workflow with thaw-and-use cells

Standardized Reagents Improve Results

  • Thaw-and-use cell format provides significant time and labor savings over traditional methods while reducing variability.
  • Kit includes all of the required reagents in standardized formats.
  • Easily amenable to high-throughput workflows.

The Assay Principle

The PD-1+TIGIT Combination Bioassay is a bioluminescent cell-based assay that overcomes the limitations of existing assays and can be used to measure the potency and stability of antibodies and other biologics targeting PD-1 and TIGIT.

14847ma-w
Representation of the PD-1+TIGIT Combination Bioassay. The bioassay consists of two genetically engineered cell lines, PD-1+TIGIT Effector Cells and PD-L1+CD155 aAPC/CHO-K1 Cells. Panel A. When co-cultured, PD-1 inhibits TCR pathway-activated luminescence, and TIGIT inhibits CD226 pathway-activated luminescence. The addition of anti-PD-1 Ab blocks PD-1 binding to PD-L1, resulting in full TCR pathway activation. The addition of anti-TIGIT Ab blocks the TIGIT/CD155 interaction, thereby re-establishing CD226 pathway-activated luminescence. Blocking of PD-1/PD-L1 and TIGIT/CD155 can be detected in a dose-dependent manner by addition of Bio-Glo™ Reagent and quantitation with a luminometer.  Panel B. When co-cultured with Effector Cells that do not express PD-1 or TIGIT (Cat.# J1920), TCR activation and CD226/CD155 induce luminescence. 

Assay Performance Data

Accuracy and Precision are critical to bioassays and the development of biologics. The PD-1+TIGIT Combination Bioassay is both accurate and precise. Accuracy is a measure of how close results are to a target or reference value. Precision is a measure of repeatability. This assay was developed and prequalified according to ICH guidelines for accuracy and precision giving it the performance characteristics required for many applications of a bioassay used for antibody drug discovery research and development.

Accuracy for Assay Performance Data
Accurate, but not precise

Accuracy
Measure of ability to replicated a reference or "target" value.
IntraLab Precision
Precise, but not accurate

IntraLab Precision

Measure of repeatability from multiple assays of the same homogeneous sample under the same operating conditions over a short time (same analyst; same lab; same day).

Intermediate Precision Data Target 3
Accurate and precise

Intermediate Precision

Measure of repeatability of multiple assays of the same homogeneous sample with different analysts or equipment or on different days.

32454752-data-linear
Linear

Linearity

Ability of your assay to provide measured values that are proportional to the concentration of the sample.

Accuracy

Expected Relative Potency Recovery
50% 95.3%
70% 105.5%
140% 104.9%
200% 109.9%

Repeatability (100% reference, %CV)

4.1%

Intermediate Precision (%CV)

10.4%

Linearity

r 2 = 0.999 (50-200% range)
y = 1.131x + 0.028


The PD-1+TIGIT Combination Bioassay reflects the mechanism of action (MOA) and specificity of biologics designed to block the PD-1/PD-L1 and TIGIT/CD155 interaction.

The PD-1+TIGIT Combination Bioassay measures the activity of Control Ab, Anti-PD-1, and Control Ab, Anti-TIGIT.

14848mb-w
PD-1+TIGIT Effector Cells were incubated with PD-L1+CD155 aAPC/CHO-K1 Cells in the presence of serial titrations of Control Ab, Anti-TIGIT (Cat.# J2051), Control Ab, Anti-PD-1 (Cat.# J1201), anti-PD-L1 Ab (research grade) or anti-CTLA-4 (ipilimumab) blocking Abs as indicated. 
14922ma-w
PD-L1+CD155 aAPC/CHO-K1 Cells were plated overnight. The following day, a titration of a 1:1 ratio of either Control Ab, Anti-PD-1, and Control Ab, Anti-TIGIT, or a research-grade anti-PD-L1 Ab and Control Ab, Anti-TIGIT, was added, followed by PD-1+TIGIT Effector Cells. 
32454752-related-products-background

Product Kit Formats and Related Products

  • Kits are available in 1X and 5X sizes.
  • Control Ab, Anti-TIGIT, and Control Ab, Anti-PD-1, are available separately.

Specifications

You are viewing: J2211 Change Configuration

What's in the box?

Item Part # Size

PD-1+TIGIT Effector Cells

J176A 1 × 1 vial

PD-L1+CD155 aAPC/CHO-K1 Cells

J184A 1 × 1 vial

Fetal Bovine Serum

J121A 1 × 4ml

Ham's F-12 Medium

J123A 1 × 25ml

RPMI 1640 Medium

G708A 1 × 36ml

Bio-Glo™ Luciferase Assay Buffer

G719A 1 × 10ml

Bio-Glo™ Luciferase Assay Substrate

G720A 1 × 1 vial

SDS

Choose language:

Download SDSPDF (256 KB) – English (United States)

Use Restrictions

Not For Medical Diagnostic Use.

Patents and Disclaimers

NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use” means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega’s. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

Patent Pending.

U.S. Pat. No. 8,008,006 and European Pat. No. 1341808.

U.S. Pat. No. 10,077,244 and other patents.

Product cannot be used for proficiency testing.

Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.

Specifications

You are viewing: J2215 Change Configuration

What's in the box?

Item Part # Size

PD-1+TIGIT Effector Cells

J176A 5 × 1 vial

PD-L1+CD155 aAPC/CHO-K1 Cells

J184A 5 × 1 vial

Fetal Bovine Serum

J121A 5 × 4ml

Ham's F-12 Medium

J123A 5 × 25ml

RPMI 1640 Medium

G708A 5 × 36ml

Bio-Glo™ Luciferase Assay Buffer

G719A 5 × 10ml

Bio-Glo™ Luciferase Assay Substrate

G720A 5 × 1 vial

SDS

Choose language:

Download SDSPDF (256 KB) – English (United States)

Use Restrictions

Not For Medical Diagnostic Use.

Patents and Disclaimers

NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use” means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega’s. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

Patent Pending.

U.S. Pat. No. 8,008,006 and European Pat. No. 1341808.

U.S. Pat. No. 10,077,244 and other patents.

Product cannot be used for proficiency testing.

Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.

Let's find the product that meets your needs.

Talk to a Scientist

Robert

Robert

US